Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (465)	12/10/1999 7:30:00 PM
From: michael modeme	Respond to of 3044

Now the connection between disease and target proteins is becoming very clear. Molecular quantitative genetics is making many inroads into the connection in model organisms, and the techniques will be applied to humans. There are many new ways of obtaining liklihood maps to find QTLs of diseased phenotypes. Once targets are isolated, there are many new molecular methods for obtaining useful drugs. Combinatorial methods, directed evolution of nucleic acids/proteins to fit sites or catalyze reactions, phage delivery systems, etc. You are correct in pointing out that target sites are the first step, this is quite obvious. But, in a real sense, it is a necessary first step for the development of highly specific, low cost of research, drugs; and while the vast majority of target sites are currently unknown, once genome information is mulled over and analyzed, that situation will change. And it is the bioinformatics/genomics companies that will be at the heart of it. I appreciate the adivce, but I think I'll hold tight. We may have some downside, but I like to buy companies like MLNM and forget about them for years. I'm confident that MLNM is one of those stocks. Besides I'm sitting on well over 200% gain in MLNM, and can't think of a better place to put that $. Thanks again. Cheers.